SMSupriya Mallick

Supriya Mallick

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Supriya Mallick has a total of 257 co-authors. Here are the top co-authors by number of shared publications:

  • Rony Benson

    Department of Medical Oncology Regional Cancer Centre Trivandrum India

    25 shared publications
  • Pramod Kumar Julka

    Department of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India

    21 shared publications
  • Ajeet Kumar Gandhi

    Department of Radiation Oncology, Dr. Ram Manohar Lohia Institute of Medical Sciences, Lucknow, India

    12 shared publications
  • Goura Kishor Rath

    Department of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India

    12 shared publications
  • Aman Sharma

    Department of Radiation Oncology, National Cancer Institute, All India Institute of Medical Sciences, New Delhi, India

    10 shared publications
  • Dayanand Sharma

    Department of Radiation Oncology, National Cancer Instititute, All India Institute of Medical Sciences, New Delhi, India

    10 shared publications

Latest Publications

  • Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer

    by Adhar Amritt, Abhilash Dagar, Adrija Ghosh, Arjun Maiti, Jaswin Raj, Sangeeta Hazarika, Ashish Datt Upadhyay, Jitendra K. Meena, Abhinav Singhal, Aman Sharma, et al.

    Background Stereotactic ablative body radiation (SABR), combined with systemic therapy (ST), is increasingly used to improve survival in oligometastatic breast cancer (OMBC). Methods Patients with no brain or bone metastases on whole-body PET-CT received curative-intent local and systemic treatment, including SABR to metastatic site. Doses were: liver (45–50 Gy/5 fractions), peripheral lung (54 Gy/3fractions), central lung (60 Gy/8fractions), lymph nodes (30 Gy/3fractions), and peritoneal deposits (45 Gy/5fractions). Response was assessed at 3 months (RECIST v1.1); pain, gross tumour volume (GTV), planning target volume (PTV), and toxicity (CTCAE) were documented. Results From Dec 2021 to Mar 2025, 39 patients (42 sites; median age 47) were treated: liver (17), lung (14), nodes (5), other (6). At a median follow-up of 23.9 months, median PFS was 16.3 months (95% CI: 10.3–24.1); median OS was not reached; restricted mean OS for the cohort was 89.2 months. Twenty-eight patients were alive, 11 died, two were lost to follow-up. Subtypes included TNBC (36%) and HER2+ (33%), luminal B (23%). Univariate analysis showed older age, smaller PTV, and higher BED10 improved PFS; multivariate analysis confirmed age (HR 0.20, p = 0.006), PTV (HR 6.57, p = 0.001), and luminal subtype. Most common toxicity: grade 2 pain flare and hepatitis (10%). Conclusion Curative-intent treatment with SABR for visceral OMBC offers promising survival outcomes. Molecular subtyping may aid treatment selection. Clinical trial number Not applicable.


  • Emerging Corynebacterium species infections in the shadow of radiation therapy: A case series in cancer patients

    by Anil Gupta, Debasish Biswal, Abhilash Dagar, Karun Kamboj, Supriya Mallick, Aman Sharma, Bimal Kumar Das

  • Open Access

    Determinants of Quality Breast Cancer Care in India: A Tri-Perspective Multicentric Exploration among Patients, Caregivers, and Health Care Providers

    by Surendran Veeraiah, Nisha K. Jose, Neha Tojan, Ruchi Tripathi, Sridevi Veluswami, Revathy Sudhakar, Divya Rajkumar, Arup Chakraborty, Biswajit Dubashi, Budhi Singh Yadav, et al.

    Background: Breast cancer is the most common female cancer worldwide. While innovative and effective cancer therapies hold promise for improving patient outcomes, several barriers hinder their development and utilization in India. The study aims to explore the perspectives of patients, caregivers, and healthcare providers (HCPs) on the quality of breast cancer care in India. Methods: The study was conducted under the ICMR-NHRP project; the data were collected using In-depth Interviews (IDIs) and Focus Group Discussion (FGDs), among patients with breast cancer caregivers, and HCPs, in equal representation, from 13 institutions across India, categorized under six zones. A total of 293 IDIs and 39 FGD transcripts were analysed using NVivo V15 software, which were later categorized using constructs from the Consolidated Framework for Implementation Research (CFIR).Findings: Overall, 21 categories emerged and were categorized under CFIR constructs. They revealed that breast cancer care in India is shaped by intersecting systemic, cultural, and personal factors. Quality care was reported to be enhanced by treatment advancement, HCP’s ' communication, financial schemes, and other patient-centric benefits. In contrast, challenges such as financial constraints, stigma, misconceptions, and facility-related barriers were also reported. Interpretation: Regional heterogeneity in India’s breast cancer landscape highlights the inadequacy of one-size-fits-all approaches and necessitates context-specific intervention packages that are equity-driven and culturally competent. Health system interventions for breast cancer care must be tailored to address distinct systemic, cultural, and personal factors.

  • A Study of Curative-approach Treatment Along With Metastasis-Directed Stereotactic Body Radiation Therapy in Bone-Only Oligometastatic Breast Cancer

    by Abhilash Dagar, Adrija Ghosh, Abhinav Singhal, Akash Kumar, Jyoti Sharma, Aman Sharma, Ashutosh Mishra, Atul Batra, Ajay Gogia, Jaswin Raj, et al.


  • Open Access

    A protocol paper on the implementation of health care model to improve the survival of breast cancer patients in India

    by Biswajit Dubashi, Nisha K. Jose, Supriya Mallick, Budhi Singh, Ruchi Tripathi, Nandini Devi, Surendran Veeraiah

    Background: Breast cancer is the leading cause of cancer-related morbidity and mortality among Indian females, accounting for 13.5% of new cancer cases and 10.6% of all cancer deaths. The median 5-year survival rate was 73.8%, ranging from 93.3% for patients with stage I to only 24.5% for those with stage IV disease. A comprehensive package of effective interventions implemented with quality is expected to improve survival. Objectives: To develop and implement a package of interventions so that at least 80% of patients with breast cancer are provided with evidence-based quality care. Design: The proposed implementation research will follow a mixed-method approach executed at 13 sites in India. Methods: The study will be conducted in three phases. During the formative phase, facilitators and barriers in diagnostic evaluation and treatment delivery in patients with non-metastatic breast cancer will be identified using a mixed-method approach. Simultaneously, prospective baseline data collection with emphasis on selected key performance indicators (KPIs) will be done for 6 months. Results from the formative phase will be used to develop a healthcare model that will ensure evidence-based quality care for at least 80% of stage II breast cancer patients. In the implementation phase, a trial run of this health care package will be conducted, and periodic assessment of its smooth running will be ensured. Depending on the requirements of each site, two to three iterations will be done, and a final healthcare package will be fixed. This finalized model will be executed for 1 year. At the end of 1 year, selected KPIs will be reassessed. At the evaluation phase, the outcome of the model will be assessed by comparing KPIs. Even after completing this project, patients will be followed up regularly for tracking long-term outcomes. Discussion: Achieved targeted interventions will help to set up a clinical care pathway with early diagnosis, timeliness of providing treatment, reduced default and abandonment, and improved survival among breast cancer patients in India.


  • Survival and toxicity outcomes of hypofractionated conformal radiotherapy compared to conventionally fractionated radiotherapy in the treatment of diffuse intrinsic pontine gliomas

    by Abhilash Dagar, Adrija Ghosh, Aashita, Akash Kumar, Yousra Izzuddeen K. N., Karun Kamboj, Aman Sharma, Jaswin Raj, Dayanand Sharma, Supriya Mallick

    Introduction Diffuse intrinsic pontine gliomas are associated with dismal survival outcomes. Conventional fractionation radiation to a dose of 60 Gy is the standard of treatment. This retrospective review aims to compare survival and toxicity outcomes of patients treated with conventional fractionation (CF) and hypofractionation (HF) radiotherapy. Materials and methods Treatment-naïve diffuse intrinsic pontine glioma patients undergoing radical radiation were analyzed. CF was delivered to a dose of 50–60 Gy in 25–30 fractions, while HF was delivered as 38–40 Gy in 12–15 fractions. All patients were planned via the volumetric modulated arc therapy (VMAT) technique. Results A total of 64 patients were eligible for analysis. The median age of presentation was 10 years. Motor deficit was the most common presenting complaint in 51.6% of the patients, with a median symptom duration of 2 months. The pons was the most frequent site of disease epicenter in 71.8% of the patients. After a median follow-up of 9.45 months (range 0.23–72.63 months), 23 patients died, and 28 patients experienced disease progression. The unadjusted hazard ratio (HR) for death in patients treated with HF as compared to CF was 1.330 (95% CI 0.522–3.386) (p-value 0.550, by Cox regression analysis). The median OS for the entire cohort was 13.9 months, while it was 9.7 months (95% CI 5.65–13.74) and 15.1 months (95% CI 9.02–21.18) (p-value = 0.547) with CF and HF, respectively. On multivariate analysis, disease epicenter in the pons was the only significant factor associated with PFS. Hypofractionation was associated with a significantly higher aspiration rate and Ryle’s tube requirement (p-value 0.027). Conclusion Hypofractionated radiation can be considered for diffuse intrinsic pontine glioma with optimum supportive care.


  • Optimum radiation dose for palliation in head and neck squamous cell carcinoma (OpRAH) – A phase 3 randomized controlled trial

    by Supriya Mallick, Abhilash Dagar, Adrija Ghosh, Aashita, Jaswin Raj, Sangeeta Hazarika, Jitendra K. Meena, Akash Kumar, Jyoti Sharma, Smriti Panda, et al.


  • Open Access

    Clinical and toxicity outcomes with 3D based-HDR surface mold brachytherapy in skin cancer

    by Purnachandrarao Yadavalli, Vibhay Pareek, Mansi Barthwal, Rampukar Bharat, Shreejesh Mullassery, Aashita, Preeti Patil, Aman Sharma, Daya Nand Sharma, Supriya Mallick

    Introduction: Surface mold brachytherapy (SMBT) is an established treatment modality in skin cancer, especially in accessible areas, and has shown comparable outcomes to surgery. We have presented our results for the skin tumor treatment with SMBT treated with high-dose-rate (HDR) brachytherapy in terms of clinical outcomes and toxicity at our institute. Materials and Methods: In this retrospective analysis, 15 patients with skin cancer were treated with customized tube-based SMBT at our institute between January 2019 and July 2021. The patients were treated using HDR-brachytherapy using Iridium-192. The median dose was 40 Gy in 10 fractions. The dosimetric parameters were assessed, and patients were followed up as per the institutional protocol. All patients underwent individualized CT-based planning. Skin toxicity was assessed using the Dermatology Life Quality Index (DLQI). Results: With the majority of the patients being male, the median age was 59 years and the most common site affected was the face (8/15; 53.3%). Among the 15 cases, five were squamous cell carcinoma, nine were basal cell carcinoma, and a single case of sebaceous cell carcinoma. The median depth of invasion was 4 mm, and the median catheter-to-surface distance was 1 mm. The complete response rate among the 10 definitive cases was 90% and partial response in one case. The treatment was well-tolerated with no grade 3-5 toxicities. The median V95% and V90% were 94.8% and 97.1%, respectively. The mean coverage index (C.I.), dose non-uniformity ratio (DNR), and overdose volume index (ODI) were 0.97, 0.13, and 0.05, respectively. After a median follow-up of 12 months, none of the patients had recurrence. On assessment of DLQI, the scores were found to be significant in association with the tumor size and tumor site with scores favoring <2 cm and non-exposed area lesions. Conclusion: SMBT is a safe and effective treatment modality for skin tumors providing excellent response and cosmetic outcomes. It is well-tolerated and a non-invasive option for elderly patients with comorbidities and lesions in inoperable areas.